The list of low-cost drugs published by Xinjiang development and Reform Commission includes 89 kinds of Western Medicine

Source: Urumqi evening news, June 19, 2014, after the national development and Reform Commission "untied" the price of low-cost drugs, the Xinjiang Uygur Autonomous Region Development and Reform Commission also publicized the list of low-cost drugs according to the local situation, including 89 kinds of Western medicine and 147 kinds of Chinese patent medicine On Tuesday, the reporter learned from the development and Reform Commission of Xinjiang Uygur Autonomous Region that the list of low-cost drugs formulated this time is all drugs within the scope of the list of drugs priced by the development and Reform Commission of Xinjiang Uygur Autonomous Region After entering the list of low-cost drugs, the average daily consumption price of Western medicine is not more than 3 yuan, and that of Chinese patent medicine is not more than 5 yuan In the list of low-cost drugs publicized by the autonomous region, there are not only cheap and easy-to-use Western medicines such as ibuprofen, naproxen, vitamin B, dry yeast, oryzanol, glycerin, but also Chinese patent medicines such as vitamin C Yinqiao tablet, Huoxiang Zhengqi tablet, and Sanhuang tablet The retail price of these drugs is usually 2 to 3 yuan There were ethnic medicines in the original list of priced medicines, but because the daily average cost of ethnic medicines was not within 3 yuan or 5 yuan, there was no ethnic medicine in the list of low-cost medicines publicized by the autonomous region It is understood that the purpose of releasing the list of low-cost drugs is to encourage pharmaceutical companies to produce low-cost drugs, reduce the burden on patients, or it will mean that some low-cost drugs that have "disappeared" will reappear in pharmacies And local pharmaceutical companies in Xinjiang say low-cost drugs that were previously stopped may be put back on the production line Compared with 533 national low-cost drugs, there are only 236 drugs in the list of low-cost drugs in the autonomous region, which is because the national drug list is nationwide, while the list of drugs in the autonomous region is only for the drugs produced and sold by local pharmaceutical enterprises The deadline for publication of the list of low-cost drugs publicized by the development and Reform Commission of the autonomous region is June 20 Will drug companies raise the price of low-cost drugs after the focus of hot spots is "untiing"? The price of low-cost drugs is "untied" by the state, and there is a lot of room for low-cost drugs to raise their prices But do pharmaceutical companies dare to raise prices without authorization? Mao Jiong, head of Sales Department of Sinopharm Xinjiang pharmaceutical company, said the retail price of Compound Danshen tablet, a low-cost drug of the pharmaceutical company, was 10.7 yuan If according to the adjustment of the price management of low-cost drugs by the state, the daily average cost of Chinese patent medicine does not exceed 5 yuan, then a box of 100 Tablet Compound Danshen tablets, as long as the price is within 50 yuan, are in line with the regulations "But this price adjustment is impossible." Mao Jiong said that a drug is not produced by an enterprise, and the market competition for low-cost drugs is fierce, while considering the acceptance of ordinary people Therefore, low price drug pricing is enough as long as the production cost can be guaranteed Bai Ping, deputy director of the Institute of market and price of the Economic Research Institute of the development and Reform Commission of the autonomous region, believes that most commonly used low-cost drugs are produced by many enterprises and have strong market competitiveness The state's "loosening" of low-cost drugs this time aims to make rational return of drug prices through orderly competition.